13F Holdings
中文EN

BLLN BillionToOne, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2070849 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY71.9%
TTM net income YoY593.9%
TTM EPS YoY183.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin71.4%
Operating margin10.2%
Net margin11.3%
FCF margin7.8%
EBITDA margin11.9%

Returns

ROE30.2%
ROA9.1%
ROIC (approx.)—
Asset turnover0.80x

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.16x
Current ratio11.25x
Interest coverage1,655.26x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio0.3%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$305.11M$152.58M$71.73M
Cost of revenue$96.65M$71.67M$54.42M
Gross profit$208.46M$80.92M$17.31M
R&D expense$49.38M$36.60M$22.41M
SG&A expense$143.05M$91.47M$64.39M
Operating income$16.02M-$47.15M-$69.50M
Interest expense$95,000$2.39M$3.27M
Pretax income$7.76M-$41.54M-$82.67M
Income tax$305,000$29,000$9,000
Net income$7.45M-$41.57M-$82.68M
EBITDA$22.92M-$40.15M-$63.59M
EPS (basic)0.18-4.12-8.45
EPS (diluted)0.14-4.12-8.45
Weighted avg. shares (diluted)21.23M10.08M9.78M
Balance sheet
Cash & equivalents$495.98M$191.48M$97.27M
Receivables$41.62M$24.71M—
Inventory$17.55M$8.73M—
Current assets$560.56M$227.82M—
PP&E, net$20.36M$17.11M—
Total assets$632.65M$302.06M—
Current liabilities$47.96M$28.39M—
Short-term debt$0$0—
Long-term debt$57.23M$51.48M—
Total debt$57.23M$51.48M—
Total liabilities$152.55M$134.31M—
Shareholders' equity$480.11M-$251.66M-$219.05M
Net debt-$438.75M-$140.00M—
Shares outstanding—10.93M—
Cash flow statement
Operating cash flow$24.59M-$41.38M-$53.67M
Capital expenditure$8.88M$5.40M$6.17M
Free cash flow$15.71M-$46.78M-$59.85M
Investing cash flow-$8.92M-$5.43M$82.84M
Financing cash flow$288.82M$141.02M$13.40M
Depreciation & amortization$6.90M$7.00M$5.90M
Stock-based compensation$15.91M$8.36M$4.85M
Share buybacks$0$546,000$0

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.